Activation of Wnt/β-catenin pathway will induce trastuzumab resistance in breast cancer cells with HER2 overexpression, thus, knocking out Wnt3 by siRNA can result in downregulation of EMT-related expression and restoration of trastuzumab’s inhibitory effect on cell growth (186). Here, ERBB2 is linked to breast cancer.